狭心症治療薬の世界市場レポート 2025年

狭心症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で165億5,000万米ドルに成長します。予測期間の成長は、世界の肥満率の上昇、精密医療の進歩、予防心臓学への注力、患者教育への取り組み、新規治療ターゲットの研究などに起因すると考えられます。予測期間における主な動向としては、遠隔モニタリングのための遠隔医療、実臨床でのエビデンスとアウトカム研究、患者中心の薬物教育、市場参入のための戦略的提携、規制の進展、迅速な承認などが挙げられます。

心血管疾患の有病率の上昇は、今後数年間における狭心症治療薬市場の成長を促進すると予想されます。心血管疾患には、冠動脈疾患、高血圧、心不全、脳卒中など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。このような心血管疾患（CVD）の増加は、高齢化、不健康なライフスタイル、肥満の蔓延など、いくつかの要因に関連しています。硝酸薬、β遮断薬、カルシウム拮抗薬などの狭心症治療薬は、心臓への血流不足に起因する胸の痛みや不快感を和らげるのに効果的であり、患者の全体的な生活の質を向上させる。例えば、英国を拠点とする心臓血管研究の慈善団体であるBritish Heart Foundationが2024年9月に発表したデータによると、英国では約760万人が心臓・循環器系疾患に罹患しており、その内訳は男性約400万人、女性約360万人です。これらの疾患は英国における全死亡の約27％を占め、年間17万人以上、1日当たり約480人が死亡しており、これは3分に1人が死亡していることになります。したがって、心血管疾患の有病率の増加が狭心症治療薬市場の成長を促進しています。

高血圧と糖尿病の急増率は、当面の狭心症治療薬市場の拡大を刺激すると予測されています。高血圧は高い動脈血圧を特徴とし、糖尿病は血糖値の上昇を特徴とする長期的な疾患であり、狭心症のような心血管疾患の一般的な危険因子です。これらの疾患の急増は、狭心症治療に使用される薬剤の需要を増大させる。例えば、2022年6月の世界保健機関（WHO）のデータでは、2022年4月までに15,000以上の医療施設で250万人以上の高血圧症例が記録されたと報告されています。同様に、2023年6月のオーストラリア保健福祉研究所（Australian Institute of Health and Welfare）からの情報では、糖尿病に罹患したオーストラリア人の数は過去10年間で約2.8倍に急増し、46万人から130万人にエスカレートしていることが強調されています。したがって、高血圧と糖尿病の割合の増加は、狭心症治療薬市場の推進に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界狭心症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の狭心症治療薬市場：成長率分析
• 世界の狭心症治療薬市場の実績：規模と成長, 2019-2024
• 世界の狭心症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界狭心症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の狭心症治療薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硝酸塩
• 抗血小板薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 抗虚血剤
• スタチン
• 降圧剤
• 世界の狭心症治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 安定狭心症
• 不安定狭心症
• プリンツメタル狭心症
• 世界の狭心症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 経皮
• その他の投与経路
• 世界の狭心症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の狭心症治療薬市場、硝酸塩の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短時間作用型硝酸塩
• 長時間作用型硝酸塩
• 世界の狭心症治療薬市場抗血小板薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスピリン
• クロピドグレル
• 世界の狭心症治療薬市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非選択的ベータ遮断薬
• 選択的ベータ遮断薬
• 世界の狭心症治療薬市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジヒドロピリジン系カルシウムチャネル遮断薬
• 非ジヒドロピリジン系カルシウムチャネル遮断薬
• 世界の狭心症治療薬市場抗虚血剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラノラジン
• イバブラジン
• 世界の狭心症治療薬市場、スタチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトルバスタチン
• ロスバスタチン

第7章 地域別・国別分析

• 世界の狭心症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の狭心症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 狭心症治療薬市場：競合情勢
• 狭心症治療薬市場：企業プロファイル
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited
• Sanofi SA
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson
• AERIE PHARMACEUTICALS INC.
• AbbVie Inc.
• Amgen Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• H. Lundbeck A/S

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 狭心症治療薬市場2029：新たな機会を提供する国
• 狭心症治療薬市場2029：新たな機会を提供するセグメント
• 狭心症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Angina pectoris medications are employed to address the symptoms of angina pectoris, a condition characterized by chest pain or discomfort resulting from inadequate blood and oxygen supply to a portion of the heart. These drugs aim to alleviate the chest pain associated with coronary heart disease.

The primary categories of angina pectoris medications encompass nitrates, antiplatelet agents, beta-adrenergic blockers, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other pharmaceuticals. Among these, nitrates and nitrites, containing nitrogen and oxygen atoms, play a significant role in managing angina pectoris, a condition marked by chest pain due to reduced blood flow to the heart. Their usage extends to treating stable angina, unstable angina, and Prinzmetal's angina. These medications are delivered through oral, parenteral, transdermal, and various other administration routes utilized in hospitals, homecare settings, specialty clinics, and other end-user contexts.

The angina pectoris drugs market research report is one of a series of new reports from The Business Research Company that provides angina pectoris drugs market statistics, including angina pectoris drugs industry global market size, regional shares, competitors with an angina pectoris drugs market share, detailed angina pectoris drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. This angina pectoris drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angina pectoris drugs market size has grown strongly in recent years. It will grow from$12.32 billion in 2024 to $12.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, and diabetes prevalence

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $16.55 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, and research on novel therapeutic targets. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances, and expedited approvals.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the angina pectoris drug market in the coming years. Cardiovascular diseases include a variety of disorders that affect the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. This increase in cardiovascular diseases (CVD) can be linked to several factors, including an aging population, unhealthy lifestyles, and the obesity epidemic. Medications for angina pectoris, such as nitrates, beta-blockers, and calcium channel blockers, are effective in relieving chest pain and discomfort resulting from inadequate blood flow to the heart, thus improving patients' overall quality of life. For instance, data released by the British Heart Foundation, a UK-based cardiovascular research charity, in September 2024, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or about 480 deaths per day, which translates to one death every three minutes. Therefore, the increasing prevalence of cardiovascular diseases is fueling the growth of the angina pectoris drug market.

The burgeoning rates of hypertension and diabetes are projected to stimulate the expansion of the angina pectoris drug market in the foreseeable future. Hypertension, characterized by high arterial blood pressure, and diabetes, a long-term condition marked by elevated blood glucose levels, are common risk factors for cardiovascular ailments such as angina pectoris. The surge in the occurrence of these conditions amplifies the demand for medications used in angina treatment. For instance, data from the World Health Organization in June 2022 reported over 2.5 million recorded cases of hypertension across more than 15,000 healthcare facilities by April 2022. Similarly, information from the Australian Institute of Health and Welfare in June 2023 highlighted that the number of Australians affected by diabetes had surged approximately 2.8 times in the past decade, escalating from 460,000 to 1.3 million individuals. Therefore, the escalating rates of hypertension and diabetes significantly contribute to driving the angina pectoris drug market.

A prominent trend in the angina pectoris drugs market involves a focus on product innovation, with major companies within the industry leveraging new technologies to maintain their market positions. Notably, in March 2023, Hikma Pharmaceuticals plc, a UK-based firm, introduced the Labetalol Hydrochloride Injection, USP, in a prefilled syringe, which received approval from the US Food and Drug Administration (FDA). This particular product, available in hospitals in a 10 mg/2 mL PFS format, serves the purpose of treating severe hypertension and reducing blood pressure.

The key players in the angina pectoris drug market are strategically pursuing approvals for innovative products, such as the FDA's authorization of Nitrostat (Nitroglycerin Sublingual Tablets) for managing angina, aiming to better cater to their existing consumer base. Nitrostat, sanctioned by the FDA for immediate angina treatment or acute prevention, witnessed approval for sale in various strengths (0.3 mg, 0.4 mg, and 0.6 mg) in March 2022, announced by Zydus Lifesciences Ltd., an India-based pharmaceutical company. These sublingual tablets are prescribed for patients with coronary artery disease (CAD) to alleviate angina or chest discomfort, even aiding in preventing soreness before physical activity. Nitroglycerin, a part of the nitrate drug class, functions by dilating and relaxing blood vessels, thus facilitating improved blood circulation to the heart.

In November 2022, Alcon, a US-based pharmaceutical and medical device company, completed the acquisition of Aerie Pharmaceuticals Inc., a move that significantly expands Alcon's commercial product range and development pipeline. Aerie Pharmaceuticals, Inc., a US-based clinical-stage pharmaceutical firm, contributes to the angina pectoris drug market, adding depth and diversity to Alcon's portfolio, particularly in the realm of ophthalmic pharmaceuticals.

Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

North America was the largest region in the angina pectoris drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the angina pectoris drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Angina Pectoris Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angina pectoris drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angina pectoris drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The angina pectoris drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Nitrates; Antiplatelet Agents; Beta-adrenergic Blocking Agents; Calcium Channel Blockers; Anti-ischemic Agents; Statins; Antihypertensive Agents; Other Drugs
• 2) By Indication: Stable Angina; Unstable Angina; Prinzmetal's Angina
• 3) By Route of Administration: Oral; Parenteral; Transdermal; Other Route Of Administrations
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Nitrates: Short-Acting Nitrates; Long-Acting Nitrates
• 2) By Antiplatelet Agents: Aspirin; Clopidogrel
• 3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers; Selective Beta Blockers
• 4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers; Non-dihydropyridine Calcium Channel Blockers
• 5) By Anti-Ischemic Agents: Ranolazine; Ivabradine
• 6) By Statins: Atorvastatin; Rosuvastatin
• Companies Mentioned: Astellas Pharma Inc.; Bayer AG; Novartis AG; AstraZeneca PLC; Bausch Health Companies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Angina Pectoris Drugs Market Characteristics

3. Angina Pectoris Drugs Market Trends And Strategies

4. Angina Pectoris Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Angina Pectoris Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Angina Pectoris Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Angina Pectoris Drugs Market Growth Rate Analysis
• 5.4. Global Angina Pectoris Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Angina Pectoris Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Angina Pectoris Drugs Total Addressable Market (TAM)

6. Angina Pectoris Drugs Market Segmentation

• 6.1. Global Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrates
• Antiplatelet Agents
• Beta-adrenergic Blocking Agents
• Calcium Channel Blockers
• Anti-ischemic Agents
• Statins
• Antihypertensive Agents
• 6.2. Global Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stable Angina
• Unstable Angina
• Prinzmetal's Angina
• 6.3. Global Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Transdermal
• Other Route Of Administrations
• 6.4. Global Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Nitrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Nitrates
• Long-Acting Nitrates
• 6.6. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Antiplatelet Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Clopidogrel
• 6.7. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Beta-Adrenergic Blocking Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Selective Beta Blockers
• Selective Beta Blockers
• 6.8. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridine Calcium Channel Blockers
• Non-dihydropyridine Calcium Channel Blockers
• 6.9. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Anti-Ischemic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranolazine
• Ivabradine
• 6.10. Global Angina Pectoris Drugs Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Rosuvastatin

7. Angina Pectoris Drugs Market Regional And Country Analysis

• 7.1. Global Angina Pectoris Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Angina Pectoris Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Angina Pectoris Drugs Market

• 8.1. Asia-Pacific Angina Pectoris Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Angina Pectoris Drugs Market

• 9.1. China Angina Pectoris Drugs Market Overview
• 9.2. China Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Angina Pectoris Drugs Market

• 10.1. India Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Angina Pectoris Drugs Market

• 11.1. Japan Angina Pectoris Drugs Market Overview
• 11.2. Japan Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Angina Pectoris Drugs Market

• 12.1. Australia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Angina Pectoris Drugs Market

• 13.1. Indonesia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Angina Pectoris Drugs Market

• 14.1. South Korea Angina Pectoris Drugs Market Overview
• 14.2. South Korea Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Angina Pectoris Drugs Market

• 15.1. Western Europe Angina Pectoris Drugs Market Overview
• 15.2. Western Europe Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Angina Pectoris Drugs Market

• 16.1. UK Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Angina Pectoris Drugs Market

• 17.1. Germany Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Angina Pectoris Drugs Market

• 18.1. France Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Angina Pectoris Drugs Market

• 19.1. Italy Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Angina Pectoris Drugs Market

• 20.1. Spain Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Angina Pectoris Drugs Market

• 21.1. Eastern Europe Angina Pectoris Drugs Market Overview
• 21.2. Eastern Europe Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Angina Pectoris Drugs Market

• 22.1. Russia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Angina Pectoris Drugs Market

• 23.1. North America Angina Pectoris Drugs Market Overview
• 23.2. North America Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Angina Pectoris Drugs Market

• 24.1. USA Angina Pectoris Drugs Market Overview
• 24.2. USA Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Angina Pectoris Drugs Market

• 25.1. Canada Angina Pectoris Drugs Market Overview
• 25.2. Canada Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Angina Pectoris Drugs Market

• 26.1. South America Angina Pectoris Drugs Market Overview
• 26.2. South America Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Angina Pectoris Drugs Market

• 27.1. Brazil Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Angina Pectoris Drugs Market

• 28.1. Middle East Angina Pectoris Drugs Market Overview
• 28.2. Middle East Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Angina Pectoris Drugs Market

• 29.1. Africa Angina Pectoris Drugs Market Overview
• 29.2. Africa Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Angina Pectoris Drugs Market Competitive Landscape And Company Profiles

• 30.1. Angina Pectoris Drugs Market Competitive Landscape
• 30.2. Angina Pectoris Drugs Market Company Profiles
  • 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Angina Pectoris Drugs Market Other Major And Innovative Companies

• 31.1. Merck & Co Inc.
• 31.2. Eli Lilly and Company
• 31.3. Pfizer Inc.
• 31.4. Abbott Laboratories
• 31.5. Sun Pharmaceutical Industries Limited
• 31.6. Sanofi SA
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Bristol-Myers Squibb Company
• 31.9. Johnson & Johnson
• 31.10. AERIE PHARMACEUTICALS INC.
• 31.11. AbbVie Inc.
• 31.12. Amgen Inc.
• 31.13. Gilead Sciences Inc.
• 31.14. GlaxoSmithKline plc
• 31.15. H. Lundbeck A/S

32. Global Angina Pectoris Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Angina Pectoris Drugs Market

34. Recent Developments In The Angina Pectoris Drugs Market

35. Angina Pectoris Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Angina Pectoris Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Angina Pectoris Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Angina Pectoris Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer